IP Verse

Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator

Patent No. EP3203840 (titled "Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator") was filed by Vertex Pharmaceuticals Incorporated on Oct 6, 2015. The application was issued on Aug 5, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKMay 5, 2021ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3203840

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP15849396A
Filing Date
Oct 6, 2015
Status
Opposition Rejected
Mar 21, 2025
Publication Date
Aug 5, 2020
External Links
Slate, Register , Google Patents